The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
May 15th 2024
These data highlighted patient-reported and clinical outcomes among those with psoriasis, with data drawn retrospectively from Germany, Poland, Czech Republic, Japan, and Canada.
Jerry Bagel: Discussing Treatment Options with Patients
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
Jerry Bagel: Approaching Psoriasis Treatment Based on Location
As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.
Jerry Bagel: Research in Eczema Is Lacking, Despite Progress in Psoriasis
Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.
Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.
Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients
As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.
Most Patients with Plaque Psoriasis Are Dissatisfied with Their Treatment
Many psoriasis patients wish they were better informed of the significant impact their skin condition would have on their physical and mental health, according to results from Psoriasis in America 2016, a Health Union national survey.
Biosimilar Drugs for Psoriatic Arthritis, Other Conditions, One Step Closer to Approval
The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).
Psoriasis Patients Covered by Medicare Are More Likely to Discontinue Biologic Drug Therapy
Nearly 50% of Medicare patients taking biologic therapies for moderate-to-severe plaque psoriasis stop treatment within a year, reported a study by the Perelman School of Medicine at the University of Pennsylvania.